KY-05009 NEW
| Price | $43 | $65 | $119 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: KY-05009 | CAS No.: 1228280-29-2 |
| Purity: 98.06% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | KY-05009 |
| Description | KY-05009 is a chemical compound that effectively suppresses TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells, reduces TNIK protein expression and the transcriptional activity of Wnt target genes, and promotes apoptosis in cancer cells, displaying anti-cancer properties. Furthermore, it functions as an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. |
| In vitro | KY-05009 (1-3 μM; 48-72 hours; RPMI8226 cells) treatment induces caspase-dependent apoptosis in RPMI8226 cells in a dose-dependent manner. KY-05009 (3 μM; 1 hour; RPMI8226 cells) treatment suppresses the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4. KY-05009 (3 μM; 9 hours; RPMI8226 cells) treatment inhibits the IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4.KY-05009 (0.1-30 μM; 24 hours; RPMI8226 cells) treatment inhibits the proliferation of RPMI8226 cells in a dose-dependent manner. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (127.69 mM), Sonication is recommended. |
| Keywords | plasma-cells | KY05009 | MAP4K | Apoptosis | TNIK | inhibit | anti-cancer | KY-05009 | Wnt | caspase-dependent | MAPK Kinase Kinase Kinase | anti-proliferative | IL-6 | KY 05009 | Inhibitor | smyeloma | aminothiazole |
| Inhibitors Related | Urea | PRI-724 | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | (E)-Ferulic acid | Nefopam hydrochloride | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | TGF-beta/Smad Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $789.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/25kg |
NANJING PASTEUR ChEMICAL CO.,LTD
|
2023-11-01 | ||
| $43.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY